The Evaluation of Uterine Sarcomas: Tertiary Center Experience

Authors

DOI:

https://doi.org/10.21613/GORM.2023.1482

Keywords:

Endometrial stromal sarcoma, Leiomyosarcoma, Treatment, Uterine sarcoma

Abstract

BJECTIVES: To elucidate prognostic factors, determine the best course of treatment methods, and assess oncological results in individuals diagnosed with uterine sarcoma.

STUDY DESIGN: Between January 2001 and August 2023, 30 patients with uterine sarcomas (US) were included and analyzed in this cross-sectional study. Sixteen patients (53.3%) had uterine leiomyosarcoma, 6 patients (20%) had high-grade endometrial stromal sarcoma, 8 patients (26.7%) had low-grade endometrial stromal sarcoma.

RESULTS: The median follow-up of all participants was 50 months. Recurrence was detected in 43.3% of the patients. 5-year survival ratio was 73.3%, 5-year disease-free survival ratio was 66.7%, the overall survival ratio was 70% and the overall disease-free survival rate was 56.6%. No difference was observed between groups in terms of survival comparisons. No statistically significant effect of adjuvant systemic chemotherapy, adjuvant radiotherapy, and combined treatments on median overall survival and median disease-free survival was detected (p>0.05).

CONCLUSION: Uterine sarcomas are uncommon malignancies characterized by a poor prognosis, even in early stages, and they are associated with a high recurrence ratio. The most effective treatment method remains unclear to date.

Downloads

Download data is not yet available.

Downloads

Published

2024-08-25

How to Cite

1.
Yavuz O, Mankan KA, Akdoner A, Ot S, Saatli HB. The Evaluation of Uterine Sarcomas: Tertiary Center Experience. Gynecol Obstet Reprod Med [Internet]. 2024Aug.25 [cited 2024Dec.3];30(2):128-37. Available from: https://gorm.com.tr/index.php/GORM/article/view/1482

Issue

Section

Gynecology and Gynecological Oncology